Indications and uses
Clindamycin phosphate foam is indicated for topical application in the treatment of acne vulgaris in patients 12 years and older.
Clindamycin Phosphate
- Manufacturer
- Padagis Israel Pharmaceuticals Ltd
- Effective date
- 2022-04-06
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 12
- Source
- full-release
- Hydrated at
- 2026-05-31 20:40:59
Label at a glance#
ProductClindamycin Phosphate
Active ingredientCLINDAMYCIN PHOSPHATE
Label structure17 sections
Dosage and administration
Clindamycin phosphate foam is for topical use only, and not for oral, ophthalmic or intravaginal use. Apply clindamycin phosphate foam once daily to affected areas after the skin is washed with mild soap and allowed to fully dry. Use enough to cover the entire affected area. If there has been no improvement after 6 to 8 weeks or if the condition becomes worse, treatment should be discontinued. The contents of clin...
Storage and handling
Clindamycin Phosphate Foam, 1% contains 10 mg of clindamycin as clindamycin phosphate, USP per gram. The white to off-white thermolabile foam is available as follows: • 50 gram aerosol can - NDC 45802- 660 -32 • 100 gram aerosol can - NDC 45802- 660 -33 Store at 20º to 25°C (68º to 77°F) [See USP Controlled Room Temperature]. Flammable. Avoid fire, flame or smoking during and immediately following application. Con...
Contacts and useful links#
Websitewww.fda.gov
www.fda.gov/medwatch
www.fda.gov/medwatchWebsitewww.padagis.com
www.padagis.com
www.padagis.comLabel contents#
Full prescribing information#
1 INDICATIONS AND USAGE
Clindamycin phosphate foam is indicated for topical application in the treatment of acne vulgaris in patients 12 years and older.
2 DOSAGE AND ADMINISTRATION
Clindamycin phosphate foam is for topical use only, and not for oral, ophthalmic or intravaginal use.
Apply clindamycin phosphate foam once daily to affected areas after the skin is washed with mild soap and allowed to fully dry. Use enough to cover the entire affected area.
If there has been no improvement after 6 to 8 weeks or if the condition becomes worse, treatment should be discontinued.
The contents of clindamycin phosphate foam are flammable; avoid fire, flame and/or smoking during and immediately following application.
3 DOSAGE FORMS AND STRENGTHS
Clindamycin phosphate foam is a white to off-white thermolabile foam. Clindamycin phosphate foam, 1% contains 10 mg of clindamycin as clindamycin phosphate, USP per gram.
4 CONTRAINDICATIONS
Clindamycin phosphate foam is contraindicated in individuals with a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis (including pseudomembranous colitis).
5 WARNINGS AND PRECAUTIONS
5.1 Colitis
Systemic absorption of clindamycin has been demonstrated following topical use of this product. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical clindamycin. If significant diarrhea occurs, clindamycin phosphate foam should be discontinued [see Adverse Reactions (6.2)].
Severe colitis has occurred following oral or parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.
Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.
5.2 Irritation
Clindamycin phosphate foam can cause irritation. Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritation or dermatitis occurs, clindamycin should be discontinued.
Avoid contact of clindamycin phosphate foam with eyes, mouth, lips, other mucous membranes or areas of broken skin. If contact occurs, rinse thoroughly with water.
Clindamycin phosphate foam should be prescribed with caution in atopic individuals.
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 439 subjects with mild to moderate acne vulgaris were treated once daily for 12 weeks with clindamycin phosphate foam.
The incidence of adverse reactions occurring in > 1% of the subjects in clinical trials comparing clindamycin phosphate foam and its vehicle is presented in Table 1.
Table 1: Adverse Reactions Occurring in ≥ 1% of Subjects
Adverse Reactions | Number (%) of Subjects | |
Clindamycin Phosphate Foam N = 439 | Vehicle Foam N = 154 | |
Headache | 12 (3%) | 1 (1%) |
Application site burning | 27 (6%) | 14 (9%) |
Application site pruritus | 5 (1%) | 5 (3%) |
Application site dryness | 4 (1%) | 5 (3%) |
Application site reaction, not otherwise specified | 3 (1%) | 4 (3%) |
In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to clindamycin phosphate foam.
6.2 Postmarketing Experience
The following adverse reactions have been identified during post approval use of clindamycin phosphate foam: application site pain, application site erythema, diarrhea, urticaria, abdominal pain, hypersensitivity, rash, abdominal discomfort, nausea, seborrhea, application site rash, dizziness, pain of skin, colitis (including pseudomembranous colitis), and hemorrhagic diarrhea. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in association with the use of topical formulations of clindamycin. Orally and parenterally administered clindamycin have been associated with severe colitis, which may end fatally.
7 DRUG INTERACTIONS
7.1 Erythromycin
Clindamycin phosphate foam should not be used in combination with topical or oral erythromycin-containing products due to possible antagonism to its clindamycin component. In vitro studies have shown antagonism between these two antimicrobials. The clinical significance of this in vitro antagonism is not known.
7.2 Neuromuscular Blocking Agents
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, clindamycin phosphate foam should be used with caution in patients receiving such agents.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no available data on clindamycin phosphate foam use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.
Animal reproduction studies have not been conducted with clindamycin phosphate foam. No evidence of fetal harm or malformations was observed in pregnant rats and mice administered daily subcutaneous or oral doses of clindamycin salts during organogenesis at doses that produced exposures up to 84 and 42 times, respectively, the maximum recommended human dose (MRHD) of clindamycin phosphate foam based on body surface area (BSA) comparisons and assuming 100% absorption [see Data].
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
Reproduction studies have been conducted in rats and mice using subcutaneous or oral doses of clindamycin phosphate, clindamycin hydrochloride or clindamycin palmitate hydrochloride administered daily during organogenesis at doses up to the equivalent of 432 mg/kg/day clindamycin phosphate. These studies produced no evidence of fetal harm or malformations in rats or mice at exposures 84 or 42 times, respectively, the MRHD of clindamycin phosphate (i.e., 5 milliliters of clindamycin phosphate foam) based on BSA comparison and assuming 100% absorption.
8.2 Lactation
Risk Summary
There is no information on the presence of clindamycin in human milk, or the effects on the breast-fed child, or the effects on milk production following use of clindamycin phosphate foam. However, orally and parenterally administered clindamycin has been reported to appear in breast milk.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for clindamycin phosphate foam and any potential adverse effects on the breast-fed child from clindamycin phosphate foam or from the underlying maternal condition.
Clinical Considerations
If used during lactation and clindamycin phosphate foam is applied to the chest, care should be taken to avoid accidental ingestion by the infant.
8.4 Pediatric Use
Safety and effectiveness of clindamycin phosphate foam in children under the age of 12 have not been studied.
8.5 Geriatric Use
The clinical study with clindamycin phosphate foam did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects.
11 DESCRIPTION
Clindamycin phosphate foam contains clindamycin (1%) as clindamycin phosphate.
Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycin.
The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto- octopyranoside 2-(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:
Molecular Formula: C18H34CIN2O8PS Molecular Weight: 504.97 g/mol
Clindamycin phosphate foam contains clindamycin (1%) as clindamycin phosphate, USP at a concentration equivalent to 10 mg clindamycin per gram in a thermolabile hydroethanolic foam vehicle consisting of cetyl alcohol, ethanol (58%), polysorbate 60, propylene glycol, purified water, and stearyl alcohol pressurized with a hydrocarbon (propane/butane) propellant.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Mechanism of action of clindamycin in acne vulgaris is unknown [see Microbiology (12.4)].
12.2 Pharmacodynamics
Pharmacodynamics of clindamycin phosphate foam is unknown.
12.3 Pharmacokinetics
In an open label, parallel group study in 24 subjects with acne vulgaris, 12 subjects (3 male and 9 female) applied 4 grams of clindamycin phosphate foam once-daily for five days, and 12 subjects (7 male and 5 female) applied 4 grams of a clindamycin gel, 1%, once daily for five days. On Day 5, the mean Cmax and AUC(0-12) were 23% and 9% lower, respectively, for clindamycin phosphate foam than for the clindamycin gel, 1%.
Following multiple applications of clindamycin phosphate foam, less than 0.024% of the total dose was excreted unchanged in the urine over 12 hours on Day 5.
12.4 Microbiology
No microbiology studies were conducted in the clinical trials with this product.
Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing protein synthesis. Clindamycin has been shown to have in vitro activity against Propionibacterium acnes (P. acnes), an organism that has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes was not examined in clinical studies with clindamycin phosphate foam. P. acnes resistance to clindamycin has been documented.
Inducible Clindamycin Resistance: The treatment of acne with antimicrobials is associated with the development of antimicrobial resistance in P. acnes as well as other bacteria (e.g. Staphylococcus aureus, Streptococcus pyogenes). The use of clindamycin may result in developing inducible resistance in these organisms. This resistance is not detected by routine susceptibility testing.
Cross Resistance: Resistance to clindamycin is often associated with resistance to erythromycin.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenicity of a 1.2% clindamycin phosphate gel similar to clindamycin phosphate foam was evaluated by daily topical administration to mice for two years. The topical doses used in this study were approximately 3 and 15 times higher than the MRHD of clindamycin phosphate from clindamycin phosphate foam, based on BSA comparison and assuming 100% absorption. No significant increase in tumors was noted in the treated animals.
The genotoxic potential of clindamycin was evaluated in an in vitro Ames assay and in an in vivo rat micronucleus test. Both tests were negative.
Reproduction studies in rats using oral doses of clindamycin hydrochloride and clindamycin palmitate hydrochloride have revealed no evidence of impaired fertility.
14 CLINICAL STUDIES
In one multicenter, randomized, double-blind, vehicle-controlled clinical trial, subjects with mild to moderate acne vulgaris used clindamycin phosphate foam or the vehicle foam once daily for twelve weeks. Treatment response, defined as the proportion of subjects clear or almost clear, based on the Investigator Static Global Assessment (ISGA), and the mean percent reductions in lesion counts at the end of treatment in this study are shown in Table 2.
Table 2: Efficacy Results at Week 12
Efficacy Parameters | Clindamycin Phosphate Foam N = 386 | Vehicle Foam N = 127 |
Treatment response (ISGA) | 31% | 18%* |
Percent reduction in lesion counts | ||
Inflammatory Lesions | 49% | 35%* |
Noninflammatory Lesions | 38% | 27%* |
Total Lesions | 43% | 31%* |
*P<0.05
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
Clindamycin Phosphate Foam, 1% contains 10 mg of clindamycin as clindamycin phosphate, USP per gram.
The white to off-white thermolabile foam is available as follows:
- 50 gram aerosol can - NDC 45802-660-32
- 100 gram aerosol can - NDC 45802-660-33
16.2 Storage and Handling
Store at 20º to 25°C (68º to 77°F) [See USP Controlled Room Temperature].
Flammable. Avoid fire, flame or smoking during and immediately following application.
Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperature above 120°F (49°C).
Keep out of reach of children.
17 PATIENT COUNSELING INFORMATION
See FDA-Approved patient labeling (Patient Information).
17.1 Instructions for Use
- Patients should be advised to wash their skin with mild soap and allow it to dry before applying clindamycin phosphate foam.
- Patients should use enough clindamycin phosphate foam to cover the face and to apply once daily.
- Patients should dispense clindamycin phosphate foam directly into the cap or onto a cool surface.
- Patients should wash their hands after applying clindamycin phosphate foam.
17.2 Skin Irritation
Clindamycin phosphate foam may cause irritation such as erythema, scaling, itching, burning, or stinging. Patients should be advised to discontinue use if excessive irritancy or dermatitis occur.
17.3 Colitis
In the event a patient treated with clindamycin phosphate foam experiences severe diarrhea or gastrointestinal discomfort, clindamycin phosphate foam should be discontinued and a physician should be contacted.
Manufactured by Padagis
Yeruham, Israel
Distributed By Padagis
Allegan, MI 49010
Rev 02-22
4T500 RC J5
Pharmacist-Detach here and Give Instructions to Patient
Patient Information
Patient Information
Clindamycin Phosphate (klin-da-MYE-sin fos-fate) Foam, 1%
Important Information: Clindamycin phosphate foam is for use on the skin only. Do not use clindamycin phosphate foam in your eyes, mouth or vagina.
What is clindamycin phosphate foam?
Clindamycin phosphate foam is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years and older.
It is not known if clindamycin phosphate foam is safe and effective in children under 12 years of age.
Who should not use clindamycin phosphate foam?
Do not use clindamycin phosphate foam if you:
- have Crohn’s disease
- have ulcerative colitis
- have had inflammation of the colon (colitis) or severe diarrhea with past antibiotic use
Tell your doctor if you are not sure if you have any of the conditions listed above.
What should I tell my doctor before using clindamycin phosphate foam?
Before using clindamycin phosphate foam, tell your doctor about all of your medical conditions, including if you:
- have or have had bowel problems (such as Crohn’s disease, ulcerative colitis, colitis)
- have or have had eczema or other skin problems
- are planning to have surgery. Clindamycin phosphate foam may affect how certain medicines work that may be given during surgery.
- are pregnant or plan to become pregnant. It is not known if clindamycin phosphate foam may harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if clindamycin phosphate passes into your breast milk. Talk to your doctor about using clindamycin phosphate foam while breastfeeding. If you use clindamycin phosphate foam while breastfeeding and clindamycin phosphate foam is applied on the chest, take care to avoid getting clindamycin phosphate foam into your baby’s mouth.
Tell your doctor about all the medicines you take including prescription and over-the-counter medicines, vitamins and herbal supplements. Clindamycin phosphate foam may affect the way other medicines work and other medicines may affect how clindamycin phosphate foam works.
Especially tell your doctor if you take medicine by mouth that contains erythromycin or use products on your skin that contain erythromycin.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
How should I use clindamycin phosphate foam?
- Use clindamycin phosphate foam exactly as your doctor tells you to use it. See the detailed “Instructions for Use” for directions about how to apply clindamycin phosphate foam correctly.
- Wash your skin with mild soap and water and dry before applying clindamycin phosphate foam.
- Apply clindamycin phosphate foam 1 time each day to the affected skin area. You should apply enough clindamycin phosphate foam to cover the entire affected area.
- Dispense clindamycin phosphate foam directly into the cap. Do not dispense clindamycin phosphate foam directly onto your hands or face, because the foam will begin to melt on contact with warm skin.
- Wash your hands after applying clindamycin phosphate foam.
What should I avoid while using clindamycin phosphate foam?
- Clindamycin phosphate foam is flammable. Avoid fire, flames, or smoking during and right after you apply clindamycin phosphate foam to your skin.
- Avoid getting clindamycin phosphate foam in or near your eyes, mouth, lips, or broken skin. If you get clindamycin phosphate foam in your eyes, mouth, on lips or broken skin, rinse well with water.
What are possible side effects with clindamycin phosphate foam?
Clindamycin phosphate foam may cause serious side effects, including:
- Inflammation of the colon (colitis). Diarrhea, bloody diarrhea, and colitis has happened in people who use clindamycin phosphate foam. Stop using clindamycin phosphate foam and call your doctor right away if you have severe stomach (abdominal) cramps, watery diarrhea, or bloody diarrhea during treatment, and for several weeks after treatment, with clindamycin phosphate foam.
- Skin irritation. Stop using clindamycin phosphate foam and call your doctor if you develop skin irritation during treatment with clindamycin phosphate foam.
The most common side effects of clindamycin phosphate foam include headache and application site reactions (including burning, itching, and dryness).
These are not all the possible side effects of clindamycin phosphate foam.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store clindamycin phosphate foam?
- Store clindamycin phosphate foam at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep clindamycin phosphate foam away from heat. Never throw the can into a fire, even if the can is empty.
- Do not store clindamycin phosphate foam at temperatures above 120°F (49°C).
- Do not break through (puncture) the clindamycin phosphate foam can.
Keep clindamycin phosphate foam and all medicines out of the reach of children.
General information about the safe and effective use of clindamycin phosphate foam.
Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflet. Do not use clindamycin phosphate foam for a condition for which it was not prescribed. Do not give clindamycin phosphate foam to other people, even if they have the same symptoms you have. It may harm them.
You can also ask your pharmacist or doctor for information about clindamycin phosphate foam that is written for health professionals.
What are the ingredients in clindamycin phosphate foam?
Active ingredient: clindamycin phosphate
Inactive ingredients: cetyl alcohol, ethanol (58%), polysorbate 60, propylene glycol, purified water, and stearyl alcohol. The can is pressurized with a hydrocarbon (propane/butane) propellant.
This Patient Information has been approved by the U.S. Food and Drug Administration.
Instructions for Use
Instructions for Use
Clindamycin Phosphate (klin-da-MYE-sin fos-fate) Foam, 1%
Important Information: Clindamycin phosphate foam is for use on the skin only. Do not use clindamycin phosphate foam in your eyes, mouth or vagina.
 | Step 1: Remove the clear cap from the clindamycin phosphate foam can. |
 | Step 2: Hold the can upright and firmly press the nozzle to dispense clindamycin phosphate foam into the clear cap. |
 |
|
 |
|
 | Step 3: Pick up small amounts of clindamycin phosphate foam with your fingertips and gently rub the foam into the affected area until the foam disappears. Step 4: Wash your hands after applying clindamycin phosphate foam.
|
How should I store clindamycin phosphate foam?
- Store clindamycin phosphate foam at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep clindamycin phosphate foam away from heat. Never throw the can into a fire, even if the can is empty.
- Do not store clindamycin phosphate foam at temperatures above 120°F (49°C).
- Do not break through (puncture) the clindamycin phosphate foam can.
Keep clindamycin phosphate foam and all medicines out of the reach of children.
The Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
Manufactured by
Padagis
Yeruham, Israel
Distributed By
Padagis
Allegan, MI 49010
Rev 02-22
4T500 RC J5
Principal Display Panel - 50 g Carton
NDC 45802-660-32
Rx Only
Clindamycin Phosphate Foam, 1%
50g
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
DailyMed RxNorm Mappings#
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| CLINDAMYCIN Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20210811 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 45802-660-32 | Clindamycin Phosphate | 1 in 1 CARTON | AEROSOL, FOAM | 1 | 12 | |
| 45802-660-32 | Clindamycin Phosphate | 50 g in 1 CAN | AEROSOL, FOAM | 50 | 12 | |
| 45802-660-33 | Clindamycin Phosphate | 100 g in 1 CAN | AEROSOL, FOAM | 100 | 12 | |
| 45802-660-33 | Clindamycin Phosphate | 1 in 1 CARTON | AEROSOL, FOAM | 1 | 12 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 45802-660-32 | GM - Gram | 45802-660 | f14bf9a6-7d1f-4a17-bcba-ec6ca2f8591c | 1 | 2012-07-24 |
| 45802-660-33 | GM - Gram | 45802-660 | 07e2ca88-83ee-4d43-bcbb-9611d88b9ba9 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CLINDAMYCIN PHOSPHATE | ACTIVE INGREDIENT | EH6D7113I8 | 8 | |
| CLINDAMYCIN | ACTIVE MOIETY | 3U02EL437C | 8 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 8 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 8 | |
| POLYSORBATE 60 | INACTIVE INGREDIENT | CAL22UVI4M | 8 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 8 | |
| STEARYL ALCOHOL | INACTIVE INGREDIENT | 2KR89I4H1Y | 8 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 8 |
Products#
Every source-derived product name is available through these pages.
- Clindamycin Phosphate
- CLINDAMYCIN
- ALCOHOL
- POLYSORBATE 60
- PROPYLENE GLYCOL
- WATER
- STEARYL ALCOHOL
- CETYL ALCOHOL
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 45802-660 | 45802-660-32, 45802-660-33 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CLINDAMYCIN PHOSPHATE | EH6D7113I8 | ACTIM |
| ALCOHOL | 3K9958V90M | IACT |
| POLYSORBATE 60 | CAL22UVI4M | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
| STEARYL ALCOHOL | 2KR89I4H1Y | IACT |
| CETYL ALCOHOL | 936JST6JCN | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | AEROSOL, FOAM / TOPICAL | 37 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | AEROSOL, FOAM / TOPICAL | 30 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | AEROSOL, FOAM / TOPICAL | 37 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | AEROSOL, FOAM / TOPICAL | 30 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / TOPICAL | 82 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | AEROSOL, FOAM / TOPICAL | 37 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | AEROSOL, FOAM / TOPICAL | 30 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / TOPICAL | 82 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / TOPICAL | 82 mg |
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A090785-001 | CLINDAMYCIN PHOSPHATE | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A090785-001 | AT |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | RS | 2010-03-31 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A090785-001 | CLINDAMYCIN PHOSPHATE | 1% | AEROSOL, FOAM / TOPICAL | AT | 2010-03-31 | f41ea6bd6efb… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A090785-001 | AT | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A090785-001 | AT | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A090785-001 | AT | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A090785-001 | AT | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A090785-001 | AT | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A090785-001 | AT | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A090785-001 | AT | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A090785-001 | AT | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A090785-001 | AT | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A090785-001 | AT | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A090785-001 | AT | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A090785-001 | AT | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A090785-001 | AT | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A090785-001 | AT | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A090785-001 | AT | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A090785-001 | AT | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A090785-001 | AT | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A090785-001 | AT | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A090785-001 | AT | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A090785-001 | AT | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A090785-001 | AT | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A090785-001 | AT | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A090785-001 | AT | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A090785-001 | AT | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A090785-001 | AT | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A090785-001 | AT | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A090785-001 | AT | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A090785-001 | AT | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A090785-001 | AT | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A090785-001 | AT | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A090785-001 | AT | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A090785-001 | AT | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A090785-001 | AT | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A090785-001 | AT | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A090785-001 | AT | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A090785-001 | AT | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A090785-001 | AT | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A090785-001 | AT | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A090785-001 | AT | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A090785-001 | AT | 1 | f41ea6bd6efb… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Clindamycin Phosphate | CLINDAMYCIN PHOSPHATE | Padagis Israel Pharmaceuticals Ltd | 2e6f96d0-d928-4775-a7db-3e998fce675b | 2022-04-06 | Warnings, Adverse reactions | 45802-660-33 45802-660-32 45802-660 45802066033 45802066032 5c4e6dd8-1cba-471e-ae54-220717472f41 2e6f96d0-d928-4775-a7db-3e998fce675b |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.